Oragenics, Inc. (NYSE American: OGEN at https://www.webull.com/newslist/amex-ogen) (“Oragenics” or the “Company”), today announced that it has increased the size of its board of directors and appointed Ms. Kim Murphy to the board, effective May 1, 2020. Of the possible candidates, Kim’s extensive knowledge of vaccine development and her experience in vaccine commercialization represented what Oragenics needed as our business evolves.
Kim is highly-qualified to guide Oragenics in its new goal of creating a vaccine candidate that can wipe out the harm caused by COVID-19, and we look forward to drawing on her vaccine industry background.” Dr. Telling continued, “On behalf of the entire board of directors and our management team, I am delighted to welcome Kim to Oragenics as a member of the board.”
“I am humbled by the invitation to join Oragenics’ board of directors as it refocuses its business on developing a vaccine candidate to treat COVID-19. While I believe the challenges that the Company—and the world—face ahead are great, I believe now is an excellent time to share my vaccine marketing and commercialization experience with Oragenics’ forward-thinking management team and dynamic board.
I am eager to represent Oragenics on this new journey and I look forward to representing and collaborating with the Company’s shareholders, management team, and the other members of the board,” said Ms. Murphy.
Ms. Murphy brings a wealth of vaccine industry knowledge and experience that are highly relevant to the Company’s strategic acquisition of Noachis Terra, as well as the development of the Company’s other product candidates. Ms. Murphy is an accomplished leader and medical-industry professional with substantial experience in the vaccine development arena, having previously served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (“GSK”).
While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company Murphy also managed a 2,000-employee vaccine development, sales, manufacturing, and distribution team and was responsible for the integration planning of GSK’s acquisition of Novartis AG’s vaccine division.
Earlier in her career, she also worked in commercialization and marketing roles within Novartis Vaccines and Diagnostics Inc. and Merck & Co., Inc. Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, biotechnology industry groups, and academic and philanthropic societies. Ms. Murphy holds a B.A. degree in English from Old Dominion University and an M.B.A. degree in Marketing from Saint Joseph’s University. Following the addition of Ms. Murphy, the Company’s board will be composed of six members. You can also check idxx stock information at https://www.webull.com/newslist/nasdaq-idxx .